Benjamin D. Horne, MPH, PhD

Languages

  • English
  • Spanish

Academic Information

  • Departments: Biomedical Informatics - Adjunct Assistant Professor, Surgery - Adjunct Assistant Professor
  • Divisions: Emergency Medicine

Education History

Type School Degree
Doctoral Training University of Utah, School of Medicine
Genetic Epidemiology
Ph.D.
Graduate Training University of Utah, School of Medicine
Biostatistics
M.Stat
Graduate Training University of Utah, School of Medicine
General Public Health
M.P.H.
Undergraduate Brigham Young University
Applied Physics
B.S.

Selected Publications

Journal Article

  1. Carlquist JF, McKinney JT, Nicholas ZP, Clark JL, Kahn SF, Horne BD, Muhlestein JB, May HT, Anderson JL (2008 Aug). Rapid melting curve analysis for genetic variants that underlie inter-individual variability in stable warfarin dosing. J Thromb Thrombolysis, 26(1), 1-7.
  2. Bunch TJ, Day JD, Anderson JL, Horne BD, Muhlestein JB, Crandall BG, Weiss JP, Lappe DL, Asirvatham SJ (2008 Mar 15). Frequency of helicobacter pylori seropositivity and C-reactive protein increase in atrial fibrillation in patients undergoing coronary angiography. Am J Cardiol, 101(6), 848-51.
  3. Kfoury AG, French TK, Horne BD, Rasmusson KD, Lappe DL, Rimmasch HL, Roberts CA, Evans RS, Muhlestein JB, Anderson JL, Renlund DG (2008 Mar). Incremental survival benefit with adherence to standardized heart failure core measures: a performance evaluation study of 2958 patients. J Card Fail, 14(2), 95-102.
  4. May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, Yannicelli HD, Muhlestein JB (2008 Feb 15). Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am J Cardiol, 101(4), 486-9.
  5. Rondina MT, Lappe JM, Carlquist JF, Muhlestein JB, Kolek MJ, Horne BD, Pearson RR, Anderson JL (2008). Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography. Cardiology, 109(3), 196-201.
  6. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF (2007 Nov 27). Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation, 116(22), 2563-70.
  7. Horne BD, Carlquist JF, Muhlestein JB, Nicholas ZP, Anderson JL (2007 Nov). Associations with myocardial infarction of six polymorphisms selected from a three-stage genome-wide association study. Am Heart J, 154(5), 969-75.
  8. Horne BD, Camp NJ, Carlquist JF, Muhlestein JB, Kolek MJ, Nicholas ZP, Anderson JL (2007 Oct). Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. Am Heart J, 154(4), 751-8.
  9. Bair TL, Muhlestein JB, May HT, Meredith KG, Horne BD, Pearson RR, Li Q, Jensen KR, Anderson JL, Lappe DL (2007 Sep 11). Surgical revascularization is associated with improved long-term outcomes compared with percutaneous stenting in most subgroups of patients with multivessel coronary artery disease: results from the Intermountain Heart Registry. Circulation, 116(11 Suppl), I226-31.
  10. May HT, Horne BD, Levy WC, Kfoury AG, Rasmusson KD, Linker DT, Mozaffarian D, Anderson JL, Renlund DG (2007 Aug 15). Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. Am J Cardiol, 100(4), 697-700.
  11. Drakos SG, Kfoury AG, Long JW, Stringham JC, Gilbert EM, Horne BD, Hagan MB, Nelson K, Renlund DG (2007 Aug). Similar transplantation outcomes in patients bridged with cardiac assist devices for acute cardiogenic shock versus chronic heart failure. Eur J Heart Fail, 9(8), 845-9.
  12. Gong Q, Zhang L, Vincent GM, Horne BD, Zhou Z (2007 Jul 3). Nonsense mutations in hERG cause a decrease in mutant mRNA transcripts by nonsense-mediated mRNA decay in human long-QT syndrome. Circulation, 116(1), 17-24.
  13. Drakos SG, Stringham JC, Long JW, Gilbert EM, Fuller TC, Campbell BK, Horne BD, Hagan ME, Nelson KE, Lindblom JM, Meldrum PA, Carlson JF, Moore SA, Kfoury AG, Renlund DG (2007 Jun). Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions. J Thorac Cardiovasc Surg, 133(6), 1612-9.
  14. Horne BD, Camp NJ, Anderson JL, Mower CP, Clarke JL, Kolek MJ, Carlquist JF (2007 May 22). Multiple less common genetic variants explain the association of the cholesteryl ester transfer protein gene with coronary artery disease. J Am Coll Cardiol, 49(20), 2053-60.
  15. Drakos SG, Kfoury AG, Gilbert EM, Horne BD, Long JW, Stringham JC, Campbell BA, Renlund DG (2007 Apr). Effect of reversible pulmonary hypertension on outcomes after heart transplantation. J Heart Lung Transplant, 26(4), 319-23.
  16. Anderson JL, Ronnow BS, Horne BD, Carlquist JF, May HT, Bair TL, Jensen KR, Muhlestein JB (2007 Jan 15). Usefulness of a complete blood count-derived risk score to predict incident mortality in patients with suspected cardiovascular disease. Am J Cardiol, 99(2), 169-74.
  17. Meredith KG, Horne BD, Pearson RR, Maycock CA, Lappe DL, Anderson JL, Muhlestein JB (2007 Jan 15). Comparison of effects of high (80 mg) versus low (20 mg) dose of simvastatin on C-reactive protein and lipoproteins in patients with angiographic evidence of coronary arterial narrowing. Am J Cardiol, 99(2), 149-53.
  18. May HT, Alharethi R, Anderson JL, Muhlestein JB, Reyna SP, Bair TL, Horne BD, Kfoury AG, Carlquist JF, Renlund DG (2007). Homocysteine levels are associated with increased risk of congestive heart failure in patients with and without coronary artery disease. Cardiology, 107(3), 178-84.
  19. Anderson JL, Carlquist JF, Roberts WL, Horne BD, May HT, Schwarz EL, Pasquali M, Nielson R, Kushnir MM, Rockwood AL, Bair TL, Muhlestein JB (2007 Jan). Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk? Am Heart J, 153(1), 67-73.
  20. Drakos SG, Kfoury AG, Gilbert EM, Long JW, Stringham JC, Hammond EH, Jones KW, Bull DA, Hagan ME, Folsom JW, Horne BD, Renlund DG (2007 Jan). Multivariate predictors of heart transplantation outcomes in the era of chronic mechanical circulatory support. Ann Thorac Surg, 83(1), 62-7.
  21. Allen-Brady K, Horne BD, Malhotra A, Teerlink C, Camp NJ, Thomas A (2007). Analysis of high-density single-nucleotide polymorphism data: three novel methods that control for linkage disequilibrium between markers in a linkage analysis. BMC Proc, 1 Suppl 1, S160.
  22. Pope CA 3rd, Muhlestein JB, May HT, Renlund DG, Anderson JL, Horne BD (2006 Dec 5). Ischemic heart disease events triggered by short-term exposure to fine particulate air pollution. Circulation, 114(23), 2443-8.
  23. Carlquist JF, Horne BD, Muhlestein JB, Lappe DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL (2006 Dec). Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis, 22(3), 191-7.
  24. May HT, Horne BD, Anderson JL, Wolfert RL, Muhlestein JB, Renlund DG, Clarke JL, Kolek MJ, Bair TL, Pearson RR, Sudhir K, Carlquist JF (2006 Nov). Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J, 152(5), 997-1003.
  25. May HT, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Campbell BA, Kfoury AG, Lyon JL, Kim H, Renlund DG (2006 Sep 1). Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. Am J Cardiol, 98(5), 653-8.
  26. Horne BD, Camp NJ, Muhlestein JB, Cannon-Albright LA (2006 Aug). Identification of excess clustering of coronary heart diseases among extended pedigrees in a genealogical population database. Am Heart J, 152(2), 305-11.
  27. Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, Lavasani F, Wolfert RL, Pearson RR, Yannicelli HD, Anderson JL (2006 Jul 18). The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol, 48(2), 396-401.
  28. Horne BD, Carlquist JF, Cannon-Albright LA, Muhlestein JB, McKinney JT, Kolek MJ, Clarke JL, Anderson JL, Camp NJ (2006 Jul). High-resolution characterization of linkage disequilibrium structure and selection of tagging single nucleotide polymorphisms: application to the cholesteryl ester transfer protein gene. Ann Hum Genet, 70(Pt 4), 524-34.
  29. Martins TB, Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Roberts WL, Carlquist JF (2006 Jun). Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassay. Am J Clin Pathol, 125(6), 906-13.
  30. Bunch TJ, Mahapatra S, Bruce GK, Johnson SB, Miller DV, Horne BD, Wang XL, Lee HC, Caplice NM, Packer DL (2006 May 30). Impact of transforming growth factor-beta1 on atrioventricular node conduction modification by injected autologous fibroblasts in the canine heart. Circulation, 113(21), 2485-94.
  31. Drakos SG, Kfoury AG, Long JW, Stringham JC, Gilbert EM, Moore SA, Campbell BK, Nelson KE, Horne BD, Renlund DG (2006 Jan). Effect of mechanical circulatory support on outcomes after heart transplantation. J Heart Lung Transplant, 25(1), 22-8.
  32. Kolek MJ, Carlquist JF, Thaneemit-Chen S, Lazzeroni LC, Whiting BM, Horne BD, Muhlestein JB, Lavori P, Anderson JL (2005 Dec). The role of a common adenosine monophosphate deaminase (AMPD)-1 polymorphism in outcomes of ischemic and nonischemic heart failure. J Card Fail, 11(9), 677-83.
  33. Jones HU, Muhlestein JB, Jones KW, Renlund DG, Bair TL, Bunch TJ, Horne BD, Lappe DL, Anderson JL, Doty DB (2005 Aug). Early postoperative use of unfractionated heparin or enoxaparin is associated with increased surgical re-exploration for bleeding. Ann Thorac Surg, 80(2), 518-22.
  34. Whiting BM, Anderson JL, Muhlestein JB, Horne BD, Bair TL, Pearson RR, Carlquist JF (2005 Aug). Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease. Am Heart J, 150(2), 243-50.
  35. Muhlestein JB, Anderson JL, Cui C, Lan Y, Bair TL, Bunch TJ, Pearson RR, Sorensen SG, Renlund DG, Zhang L, Horne BD, Vincent GM (2005 Jul). Improved long-term survival associated with stent deployment during percutaneous coronary interventions: results from a registry of 3399 patients. Am Heart J, 150(1), 182-7.
  36. Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, Renlund DG, Muhlestein JB (2005 May 17). Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol, 45(10), 1638-43.
  37. Horton SC, Khodaverdian R, Chatelain P, McIntosh ML, Horne BD, Muhlestein JB, Long JW (2005 May 3). Left ventricular assist device malfunction: an approach to diagnosis by echocardiography. J Am Coll Cardiol, 45(9), 1435-40.
  38. Anderson JL, Muhlestein JB, Bair TL, Morris S, Weaver AN, Lappe DL, Renlund DG, Pearson RR, Jensen KR, Horne BD (2005 May 1). Do statins increase the risk of idiopathic polyneuropathy? Am J Cardiol, 95(9), 1097-9.
  39. Bunch TJ, Muhlestein JB, Bair TL, Renlund DG, Lappe DL, Jensen KR, Horne BD, Carter MA, Anderson JL (2005 Apr 1). Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure. Am J Cardiol, 95(7), 827-31.
  40. Camp NJ, Swensen J, Horne BD, Farnham JM, Thomas A, Cannon-Albright LA, Tavtigian SV (2005 Apr). Characterization of linkage disequilibrium structure, mutation history, and tagging SNPs, and their use in association analyses: ELAC2 and familial early-onset prostate cancer. Genet Epidemiol, 28(3), 232-43.
  41. Horne BD, Anderson JL, Carlquist JF, Muhlestein JB, Renlund DG, Bair TL, Pearson RR, Camp NJ (2005 Mar). Generating genetic risk scores from intermediate phenotypes for use in association studies of clinically significant endpoints. Ann Hum Genet, 69(Pt 2), 176-86.
  42. Anderson JL, Horne BD, Pennell DJ (2005). Atrial dimensions in health and left ventricular disease using cardiovascular magnetic resonance. J Cardiovasc Magn Reson, 7(4), 671-5.
  43. Clarke JL, Anderson JL, Carlquist JF, Roberts RF, Horne BD, Bair TL, Kolek MJ, Mower CP, Crane AM, Roberts WL, Muhlestein JB (2005 Jan 1). Comparison of differing C-reactive protein assay methods and their impact on cardiovascular risk assessment. Am J Cardiol, 95(1), 155-8.
  44. Ronnow BS, Reyna SP, Muhlestein JB, Horne BD, Allen Maycock CA, Bair TL, Carlquist JF, Kfoury AG, Anderson JL, Renlund DG (2005). C-reactive protein predicts death in patients with non-ischemic cardiomyopathy. Cardiology, 104(4), 196-201.
  45. Madsen TE, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Jackson JD, Lappe JM, Pearson RR, Anderson JL (2005 Jan-Feb). Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol, 25(1), 45-9.
  46. Kolek MJ, Carlquist JF, Muhlestein JB, Whiting BM, Horne BD, Bair TL, Anderson JL (2004 Dec). Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J, 148(6), 1034-40.
  47. Anderson JL, Allen Maycock CA, Lappe DL, Crandall BG, Horne BD, Bair TL, Morris SR, Li Q, Muhlestein JB (2004 Nov 15). Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol, 94(10), 1255-9.
  48. Horne BD, Camp NJ, Muhlestein JB, Cannon-Albright LA (2004 Nov 9). Evidence for a heritable component in death resulting from aortic and mitral valve diseases. Circulation, 110(19), 3143-8.
  49. Carlquist JF, Muhlestein JB, Horne BD, Hart NI, Lim T, Habashi J, Anderson JG, Anderson JL (2004 Nov). Cytomegalovirus stimulated mRNA accumulation and cell surface expression of the oxidized LDL scavenger receptor, CD36. Atherosclerosis, 177(1), 53-9.
  50. Muhlestein JB, Anderson JL, Horne BD, Carlquist JF, Bair TL, Bunch TJ, Pearson RR (2004 Nov 1). Early effects of statins in patients with coronary artery disease and high C-reactive protein. Am J Cardiol, 94(9), 1107-12.
  51. Khor LL, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Maycock CA, Anderson JL (2004 Nov 1). Sex- and age-related differences in the prognostic value of C-reactive protein in patients with angiographic coronary artery disease. Am J Med, 117(9), 657-64.
  52. Lappe JM, Muhlestein JB, Lappe DL, Badger RS, Bair TL, Brockman R, French TK, Hofmann LC, Horne BD, Kralick-Goldberg S, Nicponski N, Orton JA, Pearson RR, Renlund DG, Rimmasch H, Roberts C, Anderson JL (2004 Sep 21). Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program. Ann Intern Med, 141(6), 446-53.
  53. Yazaki Y, Muhlestein JB, Carlquist JF, Bair TL, Horne BD, Renlund DG, Anderson JL (2004 Aug). A common variant of the AMPD1 gene predicts improved survival in patients with ischemic left ventricular dysfunction. J Card Fail, 10(4), 316-20.
  54. Anderson JL, Jensen KR, Carlquist JF, Bair TL, Horne BD, Muhlestein JB (2004 Feb 1). Effect of folic acid fortification of food on homocysteine-related mortality. Am J Med, 116(3), 158-64.
  55. Horne BD, Muhlestein JB, Lappe DL, Renlund DG, Bair TL, Bunch TJ, Anderson JL (2004 Feb). Less affluent area of residence and lesser-insured status predict an increased risk of death or myocardial infarction after angiographic diagnosis of coronary disease. Ann Epidemiol, 14(2), 143-50.
  56. Horne BD, Camp NJ (2004 Jan). Principal component analysis for selection of optimal SNP-sets that capture intragenic genetic variation. Genet Epidemiol, 26(1), 11-21.
  57. Anderson JL, Horne BD, Jones HU, Reyna SP, Carlquist JF, Bair TL, Pearson RR, Lappe DL, Muhlestein JB (2004). Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease? Cardiology, 101(4), 185-93.
  58. Carlquist JF, Muhlestein JB, Horne BD, Hart NI, Bair TL, Molhuizen HO, Anderson JL (2003 Dec). The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Heart J, 146(6), 1007-14.
  59. Muhlestein JB, Anderson JL, Horne BD, Lavasani F, Allen Maycock CA, Bair TL, Pearson RR, Carlquist JF (2003 Aug). Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J, 146(2), 351-8.
  60. Zebrack JS, Anderson JL, Beddhu S, Horne BD, Bair TL, Cheung A, Muhlestein JB (2003 Jul 2). Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? J Am Coll Cardiol, 42(1), 57-63.
  61. Jackson JD, Muhlestein JB, Bunch TJ, Bair TL, Horne BD, Madsen TE, Lappe JM, Anderson JL (2003 May). Beta-blockers reduce the incidence of clinical restenosis: prospective study of 4840 patients undergoing percutaneous coronary revascularization. Am Heart J, 145(5), 875-81.
  62. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, Anderson JL (2003 Jan 21). Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation, 107(2), 258-63.
  63. Horne BD, Malhotra A, Camp NJ (2003). Comparison of linkage analysis methods for genome-wide scanning of extended pedigrees, with application to the TG/HDL-C ratio in the Framingham Heart Study. BMC Genet, 4 Suppl 1, S93.
  64. Allen Maycock CA, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Pearson RR, Li Q, Anderson JL (2002 Nov 20). Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol, 40(10), 1777-85.
  65. Beddhu S, Allen-Brady K, Cheung AK, Horne BD, Bair T, Muhlestein JB, Anderson JL (2002 Nov). Impact of renal failure on the risk of myocardial infarction and death. Kidney Int, 62(5), 1776-83.
  66. Mahdi OS, Horne BD, Mullen K, Muhlestein JB, Byrne GI (2002 Sep 24). Serum immunoglobulin G antibodies to chlamydial heat shock protein 60 but not to human and bacterial homologs are associated with coronary artery disease. Circulation, 106(13), 1659-63.
  67. Jones HU, Muhlestein JB, Jones KW, Bair TL, Lavasani F, Sohrevardi M, Horne BD, Doty D, Lappe DL (2002 Sep 24). Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports. Circulation, 106(12 Suppl 1), I19-22.
  68. Horne BD, Muhlestein JB, Strobel GG, Carlquist JF, Bair TL, Anderson JL (2002 Sep). Greater pathogen burden but not elevated C-reactive protein increases the risk of clinical restenosis after percutaneous coronary intervention. Am Heart J, 144(3), 491-500.
  69. Anderson JL, Horne BD, Carlquist JF, Bair TL, Habashi J, Hart NI, Jones SK, Muhlestein JB (2002 Sep 1). Effect of implementation of folic acid fortification of food on homocysteine concentrations in subjects with coronary artery disease. Am J Cardiol, 90(5), 536-9.
  70. Bunch TJ, Muhlestein JB, Anderson JL, Horne BD, Bair TL, Jackson JD, Li Q, Lappe DL (2002 Aug 1). Effects of statins on six-month survival and clinical restenosis frequency after coronary stent deployment. Am J Cardiol, 90(3), 299-302.
  71. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL (2002 Feb 20). C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol, 39(4), 632-7.
  72. Zhu J, Quyyumi AA, Muhlestein JB, Nieto FJ, Horne BD, Zalles-Ganley A, Anderson JL, Epstein SE (2002 Jan 15). Lack of association of Helicobacter pylori infection with coronary artery disease and frequency of acute myocardial infarction or death. Am J Cardiol, 89(2), 155-8.
  73. Zebrack JS, Anderson JL, Maycock CA, Horne BD, Bair TL, Muhlestein JB (2002 Jan 15). Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol, 89(2), 145-9.
  74. Duffin DC, Muhlestein JB, Allisson SB, Horne BD, Fowles RE, Sorensen SG, Revenaugh JR, Bair TL, Lappe DL (2001 May). Femoral arterial puncture management after percutaneous coronary procedures: a comparison of clinical outcomes and patient satisfaction between manual compression and two different vascular closure devices. J Invasive Cardiol, 13(5), 354-62.
  75. Muhlestein JB, Horne BD, Bair TL, Li Q, Madsen TE, Pearson RR, Anderson JL (2001 Feb 1). Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol, 87(3), 257-61.
  76. Zhu J, Nieto FJ, Horne BD, Anderson JL, Muhlestein JB, Epstein SE (2001 Jan 2). Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation, 103(1), 45-51.
  77. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, Anderson JL (2000 Nov 15). Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol, 36(6), 1774-80.
  78. Muhlestein JB, Horne BD, Carlquist JF, Madsen TE, Bair TL, Pearson RR, Anderson JL (2000 Oct 17). Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation, 102(16), 1917-23.
  79. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, Bunch TJ, Allen A, Trehan S, Nielson C (2000 Oct 10). Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation, 102(15), 1755-60.
  80. Anderson JL, Habashi J, Carlquist JF, Muhlestein JB, Horne BD, Bair TL, Pearson RR, Hart N (2000 Oct). A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J Am Coll Cardiol, 36(4), 1248-52.
  81. Semaan HB, Gurbel PA, Anderson JL, Muhlestein JB, Carlquist JF, Horne BD, Serebruany VL (2000 Oct). The effect of chronic azithromycin therapy on soluble endothelium-derived adhesion molecules in patients with coronary artery disease. J Cardiovasc Pharmacol, 36(4), 533-7.
  82. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, Pearson RR (2000 Sep 12). Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation, 102(11), 1227-32.
  83. Shelby JA, Mendonca MT, Horne BD, Seigel RA (2000 Jul). Seasonal variation in reproductive steroids of male and female yellow-blotched map turtles, Graptemys flavimaculata. Gen Comp Endocrinol, 119(1), 43-51.
  84. Semaan HB, Gurbel PA, Anderson JL, Muhlestein JB, Carlquist JF, Horne BD, Serebruany VL (2000). Soluble VCAM-1 and E-selectin, but not ICAM-1 discriminate endothelial injury in patients with documented coronary artery disease. Cardiology, 93(1-2), 7-10.
  85. Anderson JL, Muhlestein JB, Carlquist JF, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger MJ, Horne BD, Lim T (1999). Controlled trial of Azithromycin in patients with coronary artery disease and serologic evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation, (99), 1540-7.
  86. Anderson JL, Carlquist JF, Muhlestein JB, Horne BD, Elmer SP (1998 Jul). Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol, 32(1), 35-41.

Review

  1. Anderson JL, Carlquist JF, Horne BD, Hopkins PN (2007 Sep). Progress in unraveling the genetics of coronary artery disease and myocardial infarction. [Review]. Curr Atheroscler Rep, 9(3), 179-86.
  2. Anderson JL, Carlquist JF, Horne BD, Muhlestein JB (2003 Mar). Cardiovascular pharmacogenomics: current status, future prospects. [Review]. J Cardiovasc Pharmacol Ther, 8(1), 71-83.
  3. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF (2003). Cardiovascular pharmacogenomics: current status, future prospects. [Review]. J Cardiovasc Pharmacol Ther, (8), 71-83.

Editorial

  1. Anderson JL, Horne BD (2005 Jan). Nonlinear heart rate variability: a better ECG predictor of cardiovascular risk? Utah Special Educator, 16(1), 21-3.

Letter

  1. Zhu Y, Jenkins MM, Brass DA, Ravago PG, Horne BD, Dean SB, Drayton N (2008 Sep). Heterophilic antibody interference in an ultra-sensitive 3-site sandwich troponin I immunoassay [Letter to the editor]. Clin Chim Acta, 395(1-2), 181-2.
  2. Horne BD (2007 Jun 13). Genetic association studies and false discoveries [Letter to the editor]. JAMA, 297(22), 2477-8; author reply 2478.
  3. Horne BD (2002 Apr 13). Prevalence of surnames in each letter affects order of authors [Letter to the editor]. BMJ, 324(7342), 919.
  4. Freedman B, Muhlestein JB, Horne BD, Carlquist JF, Madsen TE, Bair TL, Pearson RR, Anderson JL (2001). Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically-demonstrated coronary artery disease [Letter to the editor]. Circulation, (104), E20-1.
  5. Gurfinkel E, Bozovich G, Mautner B, Anderson JL, Muhlestein JB, Carlquist JF, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne BD, Lim T (2000). Chlamydia pneumoniae in coronary artery disease [Letter to the editor]. Circulation, (101), W118-9.

Abstract

  1. Bair TL, Lappe DL, Ronnow BS, Carlquist JF, Renlund DG, Pearson RR, Jensen KR, Horne BD, Muhlestein JB (2006). Even mild reductions in baseline hemoglobin concentration increase the risk of death among cardiovascular patients with normal ejection fraction and no history of myocardial infarction [Abstract]. J Am Coll Cardiol, (47), 305A.
  2. Pearson RR, Thomas H, Jensen JR, Lavasani F, Horne BD, Anderson JL, Muhlestein JB (2006). The safety and efficacy of combined simvastatin and fenofibrate therapy in diabetic patients with dyslipidemia: the DIACOR study [Abstract]. J Am Coll Cardiol, (47), 316A.
  3. Horne BD, Anderson JL, Muhlestein JB, Pearson RR, Thomas H, James BC, Mower CP, Carlquist JF (2006). Pharmacogenetic warfarin-dosing algorithm is substantially improved when both VKORC1 and CYP2C9 gene variants are considered [Abstract]. J Am Coll Cardiol, (47), 288A.
  4. Healy AH, Horne BD, Renlund DG, Kfoury AG, Long JW (2006). Patient selection scale for destination therapy left ventricular assist device placement [Abstract]. ASAIO J, (52), 38A.
  5. Thomas H, Bair TL, Anderson JL, Renlund DG, Kfoury AG, Horne BD, Muhlestein JB (2006). A calculated glomerular filtration rate or a simple serum creatinine: Which is the better predictor of mortality in patients with coronary artery disease? [Abstract]. J Am Coll Cardiol, (47), 337A.
  6. Kosmicki DL, Meredith KG, Thomas H, Horne BD, Pearson RR, Bair TL, Badger RS, Barry WH, Anderson JL, Muhlestein JB (2006). Does size really matter? A comparison of drug-eluting versus bare-metal stents at different stent diameters [Abstract]. J Am Coll Cardiol, (47), 43B.
  7. Horne BD, Thomas H, Ronnow BS, Muhlestein JB, Kfoury AG, Renlund DG, Lappe DL, Kent BM, Anderson JL (2006). Risk scores combining the complete blood count and basic metabolic profile are highly predictive of death in both independent training and test populations [Abstract]. J Am Coll Cardiol, (47), 327A.
  8. Thomas H, Jensen JR, Anderson JL, Lavasani F, Pearson RR, Horne BD, Muhlestein JB (2006). Combination statin and fibrate therapy improves lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia: the DIACOR study [Abstract]. J Am Coll Cardiol, (47), 355A.
  9. Tandar A, Meredith KG, Thomas H, Bair TL, Horne BD, Barry WH, Anderson JL, Muhlestein JB (2006). Atrial fibrillation is a long-term predictor of poor outcome in acute myocardial infarction [Abstract]. J Am Coll Cardiol, (47), A201.
  10. Healy AH, Kfoury AG, Nelson DM, Horne BD, Smith HK, Kerwin BA, Wecker CR, Nelson KM, Renlund DG, Long JW (2006). Predictors of long-term survival in destination therapy left ventricular assist device patients [Abstract]. J Heart Lung Transplant, (25), S79.
  11. Muhlestein JB, Thomas H, Jensen JR, Horne BD, Lanman RB, Lavasani F, Wolfert RL, Pearson RR, Anderson JL (2006). The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR study [Abstract]. J Am Coll Cardiol, (47), 377A.
  12. Horne BD, Camp NJ, Anderson JL, Mower CP, Clarke JL, Kolek MJ, McKinney JT, Carlquist JF (2005). Assessment of associations between coronary artery disease and genetic variants in the cholesteryl ester transfer protein gene using tagging-SNPs and a test-validation study design [Abstract]. Circulation, (112(II)), 784.
  13. Ronnow BS, Muhlestein JB, Carlquist JF, Renlund DG, Lappe DL, Thomas H, Horne BD, Bair TL, Jensen KR, Anderson JL (2005). A complete blood count-derived risk score greatly improves predictive ability for mortality [Abstract]. J Am Coll Cardiol, (45), A435.
  14. Thomas H, Horne BD, Carlquist JF, Muhlestein JB, Renlund DG, Bair TL, Pearson RR, Wolfert RL, Anderson JL (2005). Sex and age-related differences in levels of lipoprotein-associated phospholipase A2 [Abstract]. Circulation, (112(II)), 774.
  15. Thomas H, Horne BD, Anderson JL, Carlquist JF, Wolfert RL, Renlund DG, Pearson RR, Muhlestein (2005). Lipoprotein-associated phopholipase A2 may differentially predict the presence of angiographic coronary artery disease and coronary death across glycemic categories [Abstract]. Circulation, (112(II)), 786.
  16. Thomas H, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Campbell BA, Renlund DG (2005). A cholesterol paradox in congestive heart failure survival? [Abstract]. J Am Coll Cardiol, (45), A182.
  17. Hall JA, Rasmusson KD, Kfoury AG, French TK, Rimmasch HL, Hofmann LC, Horne BD, Evans RS, Roberts CC, Renlund DG (2005). Successful implementation of heart failure self management improves survival [Abstract]. J Heart Lung Transpl, (24), S68.
  18. Horne BD, Camp NJ, Muhlestein JB, Cannon-Albright LA (2005). Identification of families with significant clustering of heart diseases from a genealogical population database [Abstract]. J Am Coll Cardiol, (45), A348.
  19. Drakos SG, Long JW, Stringham JC, Kfoury AG, Horne BD, Hagan MBE, Folsom JW, Gilbert EM, Renlund DG (2005). LVAD bridge to transplantation outcomes similar in acute and chronic heart failure [Abstract]. J Card Fail, (11), S136.
  20. Drakos SG, Horne BD, Gilbert EM, Kfoury AG, Long JW, Stringham JC, Campbell BA, Renlund DG (2005). Effect of reversible pulmonary hypertension on outcomes after heart transplantation in the modern era [Abstract]. J Card Fail, (11), S133.
  21. Horne BD, Anderson JL, Wolfert RL, Muhlestein JB, Renlund DG, Clarke JL, Thomas H, Kolek MJ, Bair TL, Pearson RR, Sudhir K, Carlquist JF (2005). Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease [Abstract]. J Am Coll Cardiol, (45), A224.
  22. Cui H, Anderson JL, Carlquist JF, Muhlestein JB, Bair TL, Ronnow BS, Horne BD, Cui ZC (2005). Race-Related Differences in Lipid Metabolism Genes Associated with Cardiovascular Disease [Abstract]. Circulation, (112(II)), 789.
  23. Rondina MT, Muhlestein JB, Horne BD, Bair TL, Anderson JL (2005). Long-term outcome of patients presenting with acute myocardial infarction and normal coronary arteries is just as bad as those with advanced coronary artery disease [Abstract]. J Am Coll Cardiol, (45), A235.
  24. Horne BD, Carlquist JF, Muhlestein JB, Lappe DL, James BC, Renlund DG, Clarke JL, Walker JE, Pearson RR, Jones HU, Anderson JL (2005). Pharmacogenetic dosing algorithm based on CYP2C9 genotypes for the quantitative determination of initial warfarin dose and dose adjustments [Abstract]. J Am Coll Cardiol, (45), A334.
  25. Horne BD, Muhlestein JB, Renlund DG, Carlquist JF, Bair TL, Thomas H, Campbell BA, Anderson JL (2005). Population studies of cardiovascular disease risk are limited if they lack angiographic data [Abstract]. J Am Coll Cardiol, (45), A229.
  26. Thomas H, Renlund DG, Carlquist JF, Lappe DL, Ronnow BS, Horne BD, Bair TL, Jensen KR, Anderson JL (2005). Superior predictive ability for death of a calculated basic metabolic profile risk score [Abstract]. Circulation, (112(II)), 788.
  27. Cui H, Anderson JL, Carlquist JF, Muhlestein JB, Bair TL, Ronnow BS, Horne BD, Cui ZC (2005). Han Chinese vs. Caucasian Americans: differing effects of traditional cardiovascular risk factors on the presence of coronary artery disease [Abstract]. J Am Coll Cardiol, (45), A373.
  28. Ronnow BS, Carlquist JF, Roberts WL, Horne BD, Nielson R, Kushnir MM, Rockwood AL, Bair TL, Anderson JL (2005). Cortisol/Cortisone ratio predicts impaired fasting glucose, diabetes, and coronary artery disease [Abstract]. J Am Coll Cardiol, (45), A395.
  29. Sorensen SG, Casterella PJ, Muhlestein JB, Pearson RR, Horne BD, Raleigh L, Anderson JL, Lappe DL (2004). Reduced adverse event rates after transcatheter closure of patent foramen ovale when using the Amplatzer-PFO compared to the CardioSeal device [Abstract]. J Am Coll Cardiol, (43), A377.
  30. Walker JE, Carlquist JF, Muhlestein JB, James BC, Lappe DL, Horne BD, Whiting BM, Kolek MJ, Clarke JL, Howard MP, Jones HU, Collins S, Anderson JL (2004). Cyp2C9 genotyping predicts warfarin dose and allows for quantitative anticoagulant dosing algorithms [Abstract]. Circulation, (110(III)), 740.
  31. Lappe JM, Carlquist JF, Anderson JL, Kolek MJ, Horne BD, Whiting BM, Jones HU, Pearson RR, Walker J, Muhlestein JB (2004). Soluble CD40 ligand in predicting coronary artery disease and long-term outcomes in stable patients with angiographically defined disease states [Abstract]. J Am Coll Cardiol, (43), A297.
  32. Horton SC, Chatelain PF, Khodaverdian RA, McIntosh ML, Horne BD, Muhlestein JB, Long JW (2004). Transthoracic echocardiography provides effective diagnosis of left ventricular assist device dysfunction [Abstract]. J Am Soc Echocardiogr, (17), 554.
  33. Anderson JL, Carlquist JF, Roberts WL, Horne BD, Bair TL, Schwarz EL, Pasquali M, Muhlestein JB (2004). Is asymmetric dimethylarginine a marker for diabetes, coronary artery disease, and death/myocardial infarction? Results of the Intermountain Heart Collaborative Angiographic Registry Study [Abstract]. J Am Coll Cardiol, (43), A454.
  34. Bader F, Tuttle C, Horne BD, Renlund DG (2004). The value of B-type natriuretic peptide in predicting allograft rejection in cardiac transplant recipients [Abstract]. J Heart Lung Transpl, (23), S.
  35. John JM, Anderson JL, Horne BD, Bair TL, Jensen KR, Jones HU, Renlund DG, Muhlestein JB (2004). Which white blood cell compartments predict increased cardiovascular risk? [Abstract]. J Am Coll Cardiol, (43), A278.
  36. Drakos SG, Gilbert EM, Moore SA, Stringham JC, Hammond EH, Long JW, Fuller TC, Jones WK, Bull DA, Schmitz SS, Hagan MBE, Campbell BA, Folsom JW, Stamos LA, Horne BD, Renlund DG (2004). Renal dysfunction is more likely in recipients bridged to heart transplantation with ionotropes than with left ventricular assist devices: an analysis of pre-transplant characteristics in the modern era [Abstract]. J Heart Lung Transpl, (23), S119.
  37. Reyna SP, Anderson JL, Horne BD, Bair TL, Jones J, Robinson KM, Pearson RR, Moore SA, Muhlestein JB, Renlund DG (2004). Homocysteine levels predict risk for congestive heart failure in patients with and without coronary artery disease [Abstract]. J Am Coll Cardiol, (43), A227.
  38. Lavasani F, Muhlestein JB, Einhorn D, Pearson RR, Jones HU, Horne BD, Bair TL, Thomas H, Renlund DG, Lappe DL, Anderson JL (2004). Use of either metformin or thiazolidinediones is associated with improved survival among patients with Type II diabetes from a registry of 16,203 diabetic patients [Abstract]. J Am Coll Cardiol, (43), A474.
  39. Drakos SG, Long JW, Stringham JC, Gilbert EM, Moore SA, Horne BD, Campbell BA, Nelson KE, Renlund DG (2004). Effect of mechanical circulatory support on outcomes after heart transplantation in the modern era [Abstract]. J Heart Lung Transpl, (23), S148.
  40. Khor LL, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Anderson JL, Allen Maycock CA (2004). Gender- and age-related differences in the prognostic value of C-reactive protein in patients with angiographic coronary artery disease [Abstract]. J Am Coll Cardiol, (43), A279.
  41. Clarke JL, Anderson JL, Carlquist JF, Roberts RF, Horne BD, Bair TL, Kolek MJ, Mower CP, Crane AM, Hollist TJ, Roberts WL, Muhlestein JB (2004). Do differing CRP assay methods impact cardiovascular risk assessment? [Abstract]. J Am Coll Cardiol, (43), A288.
  42. Kolek MJ, Carlquist JF, Thaneemit-Chen S, Whiting BM, Horne BD, Muhlestein JB, Lavori P, Anderson JL (2004). The role of a common adenosine monophosphate deaminase (AMPD)-1 polymorphism in outcome of ischemic and non-ischemic heart failure [Abstract]. J Am Coll Cardiol, (43), A163.
  43. Martins TB, Roberts WL, Horne BD, Anderson JL, Muhlestein JB, Carlquist JF, Hill HR (2004). Risk factor analysis of serum cytokines in coronary artery disease patients and controls using a multiplexed fluorescent immunoassay [Abstract]. J Invest Med, (52), 5127.
  44. Zhu J, Epstein SE, Muhlestein JB, Nieto FJ, Wasserman A, Horne BD, Rott D, Anderson JL (2003). Comparison of the importance of increasing pathogen burden, elevated C reactive protein, and the presence of antibodies to heat shock protein 60 on myocardial infarction or death [Abstract]. J Am Coll Cardiol, (41), 400A.
  45. Kolek MJ, Anderson JL, Muhlestein JB, Horne BD, Whiting BM, Bair TL, Lindgren ML, Carlquist JF (2003). Toll-like receptor 4 D299G polymorphism predicts lower risk of coronary artery disease and diabetes [Abstract]. Circulation, (108(IV)), 771.
  46. Horne BD, Camp NJ (2003). Principal component analysis for selection of optimal SNP-sets that capture intragenic genetic variation [Abstract]. Am J Hum Genet, (73), 379.
  47. Bair TL, Muhlestein JB, Carlquist JF, Allen Maycock CA, Pearson RR, Reyna SP, Horne BD, Anderson JL (2003). Which lipid/lipoprotein ratio best predicts angiographic coronary artery disease? [Abstract]. J Am Coll Cardiol, (41), A267-8.
  48. Horne BD, Anderson JL, Muhlestein JB, Whiting BM, Bair TL, Pearson RR, Carlquist JF (2003). Polymorphisms of the CETP, ABC, MTHFR, LPL, and PAI-1 genes predict intermediate endpoints but not angiographic coronary disease: implications for genetic research [Abstract]. J Am Coll Cardiol, (41), A249.
  49. Cheang KI, Horne BD, Muhlestein JB, Carlquist JF, Anderson JL, Hoidal JR, Terry CM (2003). Tissue factor promoter polymorphism and risk of coronary artery disease [Abstract]. Arterioscler Thromb Vasc Biol, (23), A18.
  50. Jensen KR, Anderson JL, Muhlestein JB, Renlund DG, Horne BD, Bair TL, Li Q, Lappe DL (2003). Does secondary prevention with statins eliminate the risk of hyperhomocysteinemia? [Abstract]. J Am Coll Cardiol, (41), 301A.
  51. Reyna SP, Muhlestein JB, Carlquist JF, Renlund DG, Lappe DL, Bair TL, Pearson RR, Horne BD, Allen Maycock CA, Moore SV, Anderson JL (2003). Which features of the metabolic syndrome predict the presence of angiographic coronary artery disease? [Abstract]. J Am Coll Cardiol, (41), A344-5.
  52. Bair TL, Muhlestein JB, Horne BD, Pearson RR, Li Q, Anderson JL, Lappe DL (2003). Primary use of the cutting balloon results in fewer major adverse cardiac events at six months than balloon angioplasty in a subgroup of patients with ostial/bifurcation or small vessel lesions [Abstract]. J Am Coll Cardiol, (41), 5A.
  53. Whiting BM, Anderson JL, King CA, McKinney J, Muhlestein JB, Chaichana K, Bair TL, Reyna SP, Horne BD, Carlquist JF (2003). Does the -514T gene promoter variant of hepatic lipase predict increased HDL levels and reduced risk of angiographic coronary artery disease? [Abstract]. J Am Coll Cardiol, (41), 242A.
  54. Allen Maycock CA, Muhlestein JB, Horne BD, Pearson RR, Bair TL, Lim TH, Jones HU, Reyna SP, Moore SV, Renlund DG, Anderson JL (2003). Angiotensin converting enzyme inhibition reduces elevated C-reactive protein in patients with angiographic coronary artery disease [Abstract]. J Am Coll Cardiol, (41), 391A.
  55. Lavasani F, Muhlestein JB, Einhorn D, Pearson RR, Horne BD, Bair TL, Walker J, Lappe DL, Anderson JL (2003). Baseline glycosylated hemoglobin does not predict all-cause mortality in patients with type II diabetes mellitus on different antidiabetic regimens. Results from a registry of 16,203 diabetic patients [Abstract]. Circulation, (108(IV)), 718.
  56. Jones HU, Muhlestein JB, Carlquist JF, Horne BD, Pearson RR, Allen Maycock CA, Reyna SP, Bair TL, Lappe DL, Renlund DG, Anderson JL (2003). Which features of the metabolic syndrome predict clinical outcomes (death/mycoardial infarction) in patients with angiographic coronary artery disease? [Abstract]. J Am Coll Cardiol, (41), A361.
  57. Reyna SP, Horne BD, Pearson RR, Bair TL, Allen Maycock CA, Rasmusson KD, Hall J, Moore SV, Anderson JL, Muhlestein JB, Renlund DG (2003). Do statins provide clinical benefit in high risk coronary artery disease patients with advanced left ventricular dysfunction? [Abstract]. J Am Coll Cardiol, (41), A205-6.
  58. Horne BD, Muhlestein JB, Carlquist JF, Renlund DG, Bair TL, Anderson JL (2003). Cytomegalovirus: strength of antibody response and its relationship to risk of mortality among patients with angiographic coronary disease [Abstract]. J Am Coll Cardiol, (41), 367A.
  59. Sohrevardi M, Muhlestein JB, Jones HU, Lappe DL, Renlund DG, Horne BD, Bair TL, Pearson RR, Allen Maycock CA, Moore SV, Carlquist JF, Anderson JL (2003). Troponin-I and C-reactive protein have independent value for prediction of long-term risk after acute coronary syndromes: utility of troponin-I is increased for women [Abstract]. J Am Coll Cardiol, (41), 394A.
  60. Reyna SP, Anderson JL, Horne BD, Muhlestein JB, Bair TL, Daniels B, Moore SA, Renlund DG (2003). Lack of gender-related survival difference in non-ischemic dilated cardiomyopathy [Abstract]. Circulation, (107), E7038.
  61. Allen Maycock CA, Lappe DL, Crandall BG, Muhlestein JB, Horne BD, Bair TL, Li Q, Reyna SP, Renlund DG, Anderson JL (2003). Is atrial fibrillation an inflammatory disease, reflected by elevated C-reactive protein? [Abstract]. J Am Coll Cardiol, (41), A99.
  62. Jones HU, Muhlestein JB, Lim TH, Jensen J, Pearson RR, Horne BD, Sohrevardi M, Carlquist JF, Anderson JL (2003). Short-term therapy with gatifloxacin or azithromycin prevents the acceleration of atherosclerosis after infection with Chlamydia pneumoniae in a rabbit model but does not eradicate the organism from plaque [Abstract]. J Am Coll Cardiol, (41), A289.
  63. Reyna SP, Muhlestein JB, Horne BD, Bair TL, Allen Maycock CA, Pearson RR, Moore SV, Renlund DG, Anderson JL (2003). Low socioeconomic status is more predictive of increased hazard in women than men after angiographic diagnosis of coronary artery disease [Abstract]. J Am Coll Cardiol, (41), A531.
  64. Reyna SP, French TK, Horne BD, Allen Maycock CA, Roberts CA, Pearson RR, Lappe DL, Hall J, Hofmann LC, Rimmasch HL, Anderson JL, Muhlestein JB, Renlund DG (2002). Long-term patient-reported physical and mental health status improve in congestive heart failure patients treated within a comprehensive management program [Abstract]. Circulation, (106), E119.
  65. Horne BD, Muhlestein JB, Allen Maycock CA, Carlquist JF, Lappe DL, Pearson RR, Renlund DG, Anderson JL (2002). Inadequate prediction of death by the Framingham Risk Model for patients with existing, angiographically-defined coronary artery disease [Abstract]. J Am Coll Cardiol, (39), 441A.
  66. Horne BD, Muhlestein JB, Allen Maycock CA, Carlquist JF, Lappe DL, Pearson RR, Renlund DG, Anderson JL (2002). The Intermountain Risk Model: predicting mortality by traditional and novel risk factors among patients with significant coronary disease [Abstract]. J Am Coll Cardiol, (39), A446-7.
  67. Lim TH, Muhlestein JB, Carlquist JF, Ohana B, Lipson M, Horne BD, Anderson JL (2002). Mycoplasma pneumoniae high IgA titer but not IgG predicts increased hazard of death or myocardial infarction among patients with angiographically defined coronary artery disease [Abstract]. J Am Coll Cardiol, (39), 327A.
  68. King CA, Muhlestein JB, Hart NI, Faatz JB, Mulhuizen HOF, Anderson JL, Whiting BM, Horne BD, Carlquist JF (2002). Specific polymorphism groups within a PPAR(-ABCa1 pathway are associated with future death or myocardial infarction in patients with angiographically documented coronary artery disease [Abstract]. J Am Coll Cardiol, (39), A440-1.
  69. Bunch TJ, Muhlestein JB, Anderson JL, Bair TL, Horne BD, Jackson JD, Li Q, Lappe DL (2002). Statins improve survival but not clinical restenosis: a study of 2,902 patients undergoing coronary stent deployment [Abstract]. Circulation, (105), E104.
  70. Pearson RR, Lappe DL, Horne BD, Bair TL, Allen Maycock CA, Lavasani F, Muhlestein JB (2002). Risk of nephropathy is not increased by the administration of a larger volume of contrast during coronary angiography [Abstract]. Circulation, (106), II-692.
  71. Horne BD, Muhlestein JB, Renlund DG, Bair TL, Reyna SP, Anderson JL (2002). Lower residential economic status and insurance type independently predict an increased risk of death or myocardial infarction after angiographic diagnosis of coronary artery disease [Abstract]. Circulation, (105), E90.
  72. Horton SC, McIntosh ML, Khodaverdian RA, Chatelain PF, Horne BD, Long JW (2002). Transthoracic echocardiography in routine assessment of vented electric HeartMate left ventricular assist device function [Abstract]. J Am Soc Echocardiogr, (5), 508.
  73. Jones HU, Muhlestein JB, Allen Maycock CA, Sohrevardi M, Jensen M, Pearson RR, Horne BD, Anderson JL (2002). Effects of simvastatin of C-reactive protein (ESP) Trial: A dose-response study of simvastatin and C-reactive protein [Abstract]. Circulation, (106), II-320.
  74. Casterella PJ, Mason SM, Doing T, Burke JL, Revenaugh JR, Sorensen SG, Horne BD, Pearson RR, Anderson JL, Muhlestein JB (2002). N-Acetylcysteine (MucomystTM), and Fenoldopam (CorlopamTM) do not significantly reduce the incidence of contrast induced nephropathy [Abstract]. Am J Cardiol, (90), H143.
  75. Pearson RR, French TK, Horne BD, Roberts CA, Orton JA, Allen Maycock CA, Reyna SP, Wallace DS, Lappe DL, Anderson JL, Muhlestein JB (2002). An institutional discharge medication program reduces future cardiovascular readmissions and mortality during the first year after coronary artery bypass graft surgery [Abstract]. Circulation, (106), E77.
  76. Bair TL, Renlund DG, Horne BD, Jensen KR, Li Q, Anderson JL, Lappe DL (2002). Beta-blocker therapy reduces death but not non-fatal myocardial infarction in coronary artery disease patients with no history of myocardial infarction or congestive heart failure [Abstract]. Circulation, (106), II-399.
  77. Davis BP, Muhlestein JB, Carlquist JF, Lappe JM, Horne BD, Anderson JL (2002). Interleukin-6 concentration predicts coronary artery disease better than high-sensitivity C-reactive protein [Abstract]. J Am Coll Cardiol, (39), 328A.
  78. Khodaverdian RA, Chatelain PF, Horton SC, McIntosh ML, Horne BD, Muhlestein JB, Long JW (2002). Transthoracic echocardiographic characteristics of the HeartMate left ventricular assist device inflow valve dysfunction [Abstract]. J Am Soc Echocardiogr, (5), 507.
  79. Lappe JM, Muhlestein JB, Carlquist JF, Davis BP, Horne BD, Anderson JL (2002). Interleukin-1 beta predicts death or myocardial infarction independently of high-sensitivity C-reactive protein and standard risk factors in patients with coronary artery disease [Abstract]. J Am Coll Cardiol, (39), A314-5.
  80. Pearson RR, Horne BD, Allen Maycock CA, Lappe DL, Kralick-Goldberg S, Bair TL, Orton JA, Wallace DS, Hanseen H, Renlund DG, Muhlestein JB (2002). An institutional discharge medication program reduces future cardiovascular re-admissions and mortality: an analysis of 43,841 patients with coronary artery disease [Abstract]. J Am Coll Cardiol, (39), 452A.
  81. Horne BD, Anderson JL, Muhlestein JB, Renlund DG, Allen Maycock CA, Reyna SP, King CA, Whiting BM, Chaichana K, Carlquist JF (2002). Genetic burden of polymorphisms related to lipid metabolism increases the risk of angiographic coronary artery disease [Abstract]. Circulation, (106), II-727.
  82. Zhu J, Muhlestein JB, Nieto FJ, Wasserman A, Horne BD, Anderson JL, Epstein SE (2002). Antibodies to human heat-shock protein 60 predict risk of myocardial infarction or death in women [Abstract]. J Am Coll Cardiol, (39), A338-9.
  83. Crowell PS, Berg GL, Bateman K, Reyna SP, Allen Maycock CA, Hall J, Rasmusson K, Lappe JM, Horne BD, Muhlestein JB, Anderson JL, Renlund DG (2002). Heart failure teaching and monitoring interventions improve measures of clinical practice in the primary care setting [Abstract]. Circulation, (106), E106.
  84. Jones HU, Muhlestein JB, Jones KW, Renlund DG, Bair TL, Horne BD, Lappe DL, Doty DB (2002). Increased incidence of surgical re-exploration for post-operative bleeding due to early post-operative use of unfractionated heparin or enoxaparin [Abstract]. J Am Coll Cardiol, (39), 421A.
  85. Mahdi OSM, Horne BD, Muellen K, Muhlestein JB, Byrne GI (2002). Antibodies to chlamydial heat shock protein 60 is associated with coronary artery disease, but antibodies to human heat shock protein 60 and Escherichia coli homologs are not [Abstract]. J Am Coll Cardiol, (39), 277A.
  86. Zebrack JS, Muhlestein JB, Horne BD, Bair TL, Renlund DG, Anderson JL (2001). Elevated C-reactive protein and increasing severity of coronary artery disease: Independent or interdependent predictors of risk? [Abstract]. J Am Coll Cardiol, (37), 354A.
  87. Lan YP, Bair TL, Muhlestein JB, Pearson RR, Sorenson SG, Renlund DG, Zhang L, Horne BD, Vincent GM (2001). Does stent deployment during percutaneous coronary intervention save lives? Results from a registry of 2,877 patients [Abstract]. J Am Coll Cardiol, (37), 52A.
  88. Yazaki Y, Ghaffari S, Muhlestein JB, Hart NI, Bair TL, Horne BD, Renlund DG, Anderson JL, Carlquist JF (2001). A common variant of the AMPD1 gene predicts improved survival in patients with ischemic cardiomyopathy, but not non-ischemic cardiomyopathy [Abstract]. J Am Coll Cardiol, (37), 208A.
  89. Beddhu S, Allen K, Cheung AK, Horne BD, Bair TL, Muhlestein JB, Anderson JL (2001). Serum albumin and risk of myocardial infarction in patients with renal failure [Abstract]. J Am Soc Nephrol, (12), A0989.
  90. Tabatabaei N, Alder MN, Muhlestein JB, Horne BD, Jones SK, Renlund DG, Salunkhe K, Anderson JL (2001). Statin use and reduction of plasma C-reactive protein concentration after hospitalization for coronary angiography [Abstract]. J Am Coll Cardiol, (37), 268A.
  91. Allen Maycock CA, Muhlestein JB, Renlund DG, Horne BD, Bair TL, Salunkhe K, Lavasani F, Anderson JL (2001). Elevated fasting blood glucose in non-diabetics predicts clinical restenosis: a prospective study of 2,246 patients with severe coronary artery disease [Abstract]. J Am Coll Cardiol, (37), 24A.
  92. Reyna SP, Muhlestein JB, Moore SV, Allen Maycock CA, Horne BD, Pearson RR, Walker KM, Hall J, Lappe DL, Lombardi WL, Renlund DG (2001). Elevated C-reactive protein predicts death in patients with left ventricular dysfunction in the absence of ischemic heart disease [Abstract]. Circulation, (104), II-498.
  93. Lavasani F, Muhlestein JB, Horne BD, Pearson RR, Bair TL, Kim SK, Allen Maycock CA, Salunkhe K, Renlund DG, Anderson JL (2001). Metformin versus other oral agents: Does the choice of discharge diabetic medications predict mortality? Results from a registry of 1,428 diabetic patients [Abstract]. J Am Coll Cardiol, (37), 299A.
  94. Jessup DB, Muhlestein JB, Renlund DG, Horne BD, Bair TL, Pearson RR, Anderson JL (2001). What angiographic measure of extent of coronary artery disease best predicts subsequent risk? [Abstract]. J Am Coll Cardiol, (37), 373A.
  95. Pearson RR, Horne BD, Allen Maycock CA, Lappe DL, Kralick-Goldberg S, Bair TL, Orton JA, Wallace DS, Daniels BB, Rasmusson K, Reyna SP, Renlund DG (2001). An institutional heart failure discharge medication program reduces future cardiovascular readmissions and mortality: an analysis of 19,083 heart failure patients [Abstract]. Circulation, (104), II-839.
  96. Beddhu S, Allen K, Cheung AK, Horne BD, Bair TL, Muhlestein JB, Anderson JL (2001). Renal function independent of angiographic evidence of coronary artery disease (CAD) predicts myocardial infarction and death [Abstract]. J Am Soc Nephrol, (12), A0988.
  97. Hart NI, Muhlestein JB, Molhuizen HOF, Anderson JL, Horne BD, King CA, Salunkhe K, Carlquist JF (2001). A common variant (G596A) in the ABCA1 gene is associated with diagnosis of coronary artery disease in women [Abstract]. Circulation, (104), II-609-10.
  98. Allen Maycock CA, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Pearson RR, Anderson JL (2001). Very elderly individuals with severe coronary artery disease also benefit from statin therapy [Abstract]. Circulation, (104), II-601.
  99. Zhu J, Quyyumi AA, Muhlestein JB, Nieto FJ, Horne BD, Zalles-Ganley A, Anderson JL, Epstein SE (2001). Age as a confounding factor on Helicobacter pylori infection and the risk of coronary artery disease [Abstract]. J Am Coll Cardiol, (37), 145A.
  100. Horne BD, Carlquist JF, Hart NI, Muhlestein JB, Bair TL, Pearson RR, Anderson JL (2001). Statin therapy and the cholesteryl ester transfer protein Taq1B polymorphism: lack of survival benefit for B1B1 genotype among patients with angiographically-defined coronary artery disease [Abstract]. Circulation, (104), II-449.
  101. Muhlestein JB, Hammond EH, Horne BD, Jones SK, Davis B, Habashi J, Patch JR, Lim TH, Carlquist JF (2000). Chlamydia pneumoniae infection nominally affects pharmacologically triggered thrombosis or plaque disruption in a rabbit model of pre-existing diet-induced atherosclerosis [Abstract]. Circulation, (102), II-54.
  102. Anderson JL, Habashi J, Carlquist JF, Muhlestein JB, Bair TL, Horne BD, Pearson RR, Hart N (2000). A common variant of the gene AMPD1 predicts a reduction in cardiovascular events at long-term follow-up in patients with severe coronary artery disease [Abstract]. J Am Coll Cardiol, (35), 365A.
  103. Salunkhe K, Allen Maycock CA, Muhlestein JB, Lappe DL, Horne BD, Bair TL, Handrahan D (2000). Homocysteine as a predictor of future mortality in women with angiographically defined severe coronary artery disease [Abstract]. Can J Cardiol, (16), 29B.
  104. Salunkhe K, Allen Maycock CA, Muhlestein JB, Lappe DL, Horne BD, Bair TL, Handrahan D (2000). C-reactive protein as a predictor of future mortality in women with angiographically defined severe coronary artery disease [Abstract]. Can J Cardiol, (16), 29B.
  105. Horne BD, Carlquist JF, Bair TL, Hart NI, Jones SK, Madsen TE, Anderson JL (2000). Early survival benefit of HMG-CoA reductase inhibitors in patients with coronary artery disease and high C-reactive protein [Abstract]. Circulation, (102), II-833.
  106. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Habashi J, Hart NI, Jones SK, Salunkhe K, Anderson JL (2000). Folic acid fortification and reduced homocysteine in patients with coronary artery disease [Abstract]. Circulation, (102), II-702.
  107. Muhlestein JB, Anderson JL, Carlquist JF, Horne BD, Pearson RR, Bair TL, Bunch TJ, Salunkhe K, Allen Maycock CA, Kim SK (2000). Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study [Abstract]. J Am Coll Cardiol, (35), 274A.
  108. Horne BD, Carlquist JF, Habashi J, Muhlestein JB, Greenwood J, Anderson JL (2000). Cytomegalovirus infection of human macrophages induces increased expression of scavenger receptor CD36 gene and cell-surface glycoprotein [Abstract]. J Am Coll Cardiol, (35), 268A-269A.
  109. Madsen TE, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Jackson JD, Lappe J, Pearson RR, Anderson JL (2000). Serum uric acid independently predicts future mortality in patients with severe, angiographically-defined coronary artery disease [Abstract]. J Am Coll Cardiol, (35), 284A.
  110. Horne BD, Muhlestein JB, Carlquist JF, Ohana B, Lipson M, Kahn N, Habashi J, Bair TL, Anderson JL (2000). IgA seropositivity to Mycoplasma pneumoniae predicts the diagnosis of coronary artery disease [Abstract]. J Am Coll Cardiol, (35), 312A.
  111. Bair TL, Horne BD, Lappe JM, Madsen TE, Jackson JD, Muhlestein JB (2000). Potential role of C-reactive protein in risk stratification for mild to moderate coronary artery disease [Abstract]. Circulation, (102), II-500.
  112. Salunkhe K, Muhlestein JB, Bair TL, Horne BD, Kim SK, Allen Maycock CA, Budge JP, Lewis DM, Hart NI, Renlund DG, Anderson JL (2000). Mild fasting glucose elevation increases the risk of death in non-diabetic patients undergoing percutaneous coronary intervention [Abstract]. Circulation, (102), II-847-8.
  113. Semaan H, Gurbel PA, Muhlestein JB, Carlquist JF, Anderson JL, Horne BD, Serebruany VL (2000). The Effect of Chronic Azithromycin Therapy on Soluble Endothelial-Derived Adhesion Molecules in Patients with Coronary Artery Disease [Abstract]. Circulation, (102), II-407-8.
  114. Zhu J, Nieto FJ, Horne BD, Anderson JL, Muhlestein JB, Epstein SE (2000). Prospective study of pathogen burden and risk of myocardial infarction and cardiovascular death [Abstract]. J Am Coll Cardiol, (35), 367A.
  115. Madsen TE, Muhlestein JB, Horne BD, Carlquist JF, Habashi J, Bair TL, Pearson RR, Anderson JL (1999). Homocysteine predicts mortality in patients with severe, angiographically-defined coronary artery disease [Abstract]. Circulation, (100), I-25.
  116. Pearson RR, Muhlestein JB, Horne BD, Salunkhe K, Bair TL, Li Q, Kim SK, Allen Maycock CA, Anderson JL (1999). Does intracoronary stenting protect against diabetes-related restenosis? A prospective evaluation of 4,191 patients undergoing percutaneous coronary intervention [Abstract]. Circulation, (100), I-852.
  117. Horne BD, Muhlestein JB, Bair TL, Carlquist JF, Habashi J, Salunkhe K, Anderson JL (1999). Seropositivity to Chlamydia pneumoniae, but not C-reactive protein levels or seropositivity to cytomegalovirus or Helicobacter pylori, is associated with clinical restenosis after percutaneous coronary revascularization [Abstract]. Circulation, (100), I-327.
  118. Horne BD, Muhlestein JB, Carlquist JF, Madsen TE, Bair TL, Pearson RR, Anderson JL (1999). Protection against cytomegalovirus-related mortality in patients receiving statin agents at angiographic diagnosis of coronary artery disease [Abstract]. Circulation, (100), I-720.
  119. Horne BD, Muhlestein JB, Carlquist JF, Madsen TE, Bair TL, Egger MJ, Morris MS, Peterson CR, Gardner SC, Anderson JL (1999). Therapy with statin agents, but not LDL or HDL levels, is associated with future survival at coronary artery disease diagnosis, especially in the presence of high C-reactive protein [Abstract]. J Am Coll Cardiol, (33), 244A.
  120. Duffin DC, Muhlestein JB, Kim SK, Horne BD, Allison SB, Revenaugh JR, Fowles RE, Lappe DL, Sorensen SG, Bair TL, Salunkhe K, Shepherd ML (1999). Femoral arterial puncture management after percutaneous coronary procedures: a comparison of clinical outcomes and patient satisfaction between manual compression and two different vascular closure devices [Abstract]. Circulation, (100), I-513.
  121. Muhlestein JB, Horne BD, Carlquist JF, Madsen TE, Bair TL, Egger MJ, Morris MS, Peterson CR, Anderson JL (1999). C-reactive protein and cytomegalovirus antibody levels predict mortality in patients with angiographically defined coronary artery disease [Abstract]. J Am Coll Cardiol, (33), 317A.
  122. Anderson JL, Muhlestein JB, Carlquist JF, Nielson C, Allen A, Horne BD, Brady J, Egger MJ, Limb T (1998). Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia [Abstract]. J Am Coll Cardiol, (31).
  123. Muhlestein JB, Carlquist JF, King GJ, Anderson JL, Horne BD, Elmer SP (1997). No association between prior CMV infection and the risk of clinical restenosis after percutaneous coronary interventions [Abstract]. Circulation, (96), I-650.
  124. Anderson JL, Carlquist JF, King GJ, Muhlestein JB, Horne BD, Elmer SP (1997). Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction [Abstract]. Circulation, (96), I-100.